Abstract: We all have an interest in knowing which policies work in tackling problems associated with drug use. Many members of the public, and many politicians, believe that our drug policies are not working. But the debate about how we address the challenges of mind-altering drugs is polarised in a way not seen in most other policy areas. The UK Drug Policy Commission was established to address these problems in a different way. Its aim has been to show how independent scrutiny of evidence can produce both better results and more effective use of resources in drug policy and practice. Existing drug policies have struggled to limit the damage drug use can cause, and now new challenges are emerging. The rapid development of new drugs is changing drug markets too quickly for the traditional methods we use to control drugs to be effective. The economic crisis may be impacting on the nature of drug use and drug problems and, with fewer resources, the capacity of services to respond will be limited further. Added to that, the speed and scale at which services are being devolved to a local level may create increasing and unpredictable variations in the kind of services offered in different parts of the UK. In this report, UKDPC proposes a radical rethink of how we structure our response to drug problems. It provides an analysis of the evidence for how policies and interventions could be improved, with recommendations for policymakers and practitioners to address the new and established challenges associated with drug use. UKDPC aims to foster a fresh approach to drug policy: one in which evidence takes priority, creating light rather than heat in the debate on drugs, so that we can create an environment that works to reduce dependence on drugs, safeguards communities and delivers value for money.

Abstract: In October 2010 the Minister Responsible for Drugs asked the ACMD to review khat by considering the available evidence and to advise the Government as to the current situation in the UK : the “harms caused to individuals and the societal harms in the affected UK‘s Somali, Yemeni and Ethiopian communities”.

Abstract: This Selected issue starts off by reviewing the available data on drug use among prison populations in Europe, focusing on injecting drug use and other health risk behaviours. Major health risks for drug-using prisoners, including blood-borne infections and infections that can affect all prisoners equally, such as tuberculosis, are discussed. Also mentioned is the role of prison environments, where overcrowding and unsanitary conditions are not uncommon, and the higher-than-average occurrence of psychiatric problems among prisoners. The first section concludes by describing the increased risk of death among prisoners, both in custody and after release. The second part of the report focuses on responses to the health needs of drug-using prisoners in European countries. The study looks at how the internationally recognised rights of prisoners and the European and international rules that set standards for the care of prisoners apply to those with drug problems. The administration of prison healthcare in European countries is examined, and national policies are reviewed. This is followed by an overview of the available information on drug-related service provision in Europe, from prison entry to prison release, addressing counselling, treatment of drug dependence and the prevention of infectious diseases and drug overdose.